Bayer: new clinical data for Vitrakvi
(CercleFinance.com) - Bayer has announced new data confirming the strong clinical profile of Vitrakvi (larotrectinib) for adult and pediatric patients with TRK fusion cancer (which includes a wide range of tumours), including lung and thyroid tumours.
The group wrote, "78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children".
No new safety signals have been identified.
"The consistent and durable responses as well as the safety profile from the larotrectinib data are supportive in determining the appropriate treatment option for my patients with TRK fusion cancer," said Professor Ray McDermott, St. Vincent University Hospital and Tallaght Hospital, Ireland.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The group wrote, "78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children".
No new safety signals have been identified.
"The consistent and durable responses as well as the safety profile from the larotrectinib data are supportive in determining the appropriate treatment option for my patients with TRK fusion cancer," said Professor Ray McDermott, St. Vincent University Hospital and Tallaght Hospital, Ireland.
Copyright (c) 2020 CercleFinance.com. All rights reserved.